Education History
| Fellowship |
University of Utah, Pharmacotherapy Outcomes Research Center |
Fellow |
|---|---|---|
| Graduate Training |
University of Utah |
MS |
| Doctoral Training |
University of Utah |
PharmD |
| Undergraduate |
University of Utah |
BS |
Selected Publications
Journal Article
- Varier RU, Biltaji E, Jensen K, Smith KJ, Roberts MS, LaFleur J, Nelson RE (Revise and resubmit 8/4/2014). Cost-Effectiveness Analysis of Fecal Microbiota Transplantation versus Vancomycin for Recurrent Clostridium difficile Infection. (Epub ahead of print) Clin Microbiol Infect.
- Nelson RE, Butler J, LaFleur J, Kamauu A, Schuerch M, Fosket N, DuVall SL (Submitted 6/12/2014). Determining Multiple Sclerosis Subtype from Electronic Medical Records. (Epub ahead of print) J Manag Care Pharm.
- Varier RU, Biltaji E, Jensen K, Smith KJ, Roberts MS, LaFleur J, Nelson RE (Submitted 6/5/2014). Cost-Effectiveness Analysis of Treatment Strategies for Initial Clostridium Difficile Infection. (Epub ahead of print) Infect Control Hosp Epidemiol.
- Nelson RE, Xie Y, DuVall SL, Butler J, Kamauu A, Schuerch M, Foskett N, LaFleur J (Revise and Resubmit (7/3/2014)). Multiple Sclerosis and the Risk of Infection-Related Hospitalizations and Death Among US Veterans. (Epub ahead of print) Int J MS Care.
- Lafleur J, DuVall SL, Willson T, Ginter T, Patterson O, Cheng Y, Knippenberg K, Hayden C, Alder RA, Curtis JR, Agodoa I, Nelson RE (Submitted 7/10/2014). Analysis of osteoprosis treatment patterns and outcomes among postmenopausal veterans. (Epub ahead of print) Bone.
- Xie Y, LaFleur J, Kamauu A, Schuerch M, Foskett N, Nelson RE (Submitted 7/28/2014). Rates of Early Treatment for US Veterans with Multiple Sclerosis. (Epub ahead of print) Sage Open.
- Nelson SD, LaFleur J, Hunter E, Archer M, Steinvoort C, Maden C, Oderda GM (2016). Identifying and Communicating Clinically Meaningful Drug-Drug Interactions. J Pharm Pract, 29(2), 110-5. (Read full article)
- Nelson SD, Nelson RE, Cannon GW, Lawrence P, Battistone MJ, Grotzke M, Rosenblum Y, LaFleur J (2014). Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures. Osteoporos Int, 25(12), 2701-7. (Read full article)
- Nelson RE, Hoop R, Korner E, DuVall S, Hayden CL, Knippenberg K, Morgan T, Pandya P, Han J, LaFleur J (2014). Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. Ann Pharmacother, 48(7), 826-836. (Read full article)
- Nelson RE, Battistone MJ, Ashworth WD, Barker AM, Grotzke M, Huhtala TA, Lafleur J, Tashjian RZ, Cannon GW (2014). Cost effectiveness of training rural providers to perform joint injections. Arthritis Care Res (Hoboken), 66(4), 559-66. (Read full article)
- Bellows BK, LaFleur J, Kamauu AW, Ginter T, Forbush TB, Agbor S, Supina D, Hodgkins P, DuVall SL (2014). Automated identification of patients with a diagnosis of binge eating disorder from narrative electronic health records. J Am Med Inform Assoc, 21(e1), e163-8. (Read full article)
- LaFleur J, Hoop R, Morgan T, DuVall SL, Pandya P, Korner E, Knippenberg K, Hayden C, Nelson RE (2014). High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Res Notes, 7, 266. (Read full article)
- LaFleur J, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Knippenberg K, Nelson RE (in press). Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. Gastroenterol Nurs.
- Nelson RE, Hoop R, Korner E, DuVall S, Hayden CL, Knippenberg K, Morgan T, Pandya P, Jan J, LaFleur J (in press). Predicting discontinuation of pegylated interferon due to lack of efficacy in United States veterans with chronic hepatitis C on dual therapy. Ann Pharmacother.
- Nelson RE, Nebeker JR, Hayden C, Reimer L, Kone K, LaFleur J (2013). Comparing adherence to two different HIV antiretroviral regimens: an instrumental variable analysis. AIDS Behav, 17(1), 160-7. (Read full article)
- LaFleur J, Nelson RE, Yao Y, Adler R, Nebeker J (2012). Validated risk rule using computerized data to identify males at high risk for fracture. Osteoporos Int, 23(3), 1017-27.
- Nelson RE, Nebeker JR, Sauer BC, LaFleur J (2012). Factors associated with screening or treatment initiation among male United States veterans at risk for osteoporosis fracture. Bone, 50(4), 983-8. (Read full article)
- LaFleur J, Nelson RE, Yao Y, Adler RA, Nebeker JR (2012). Validated risk rule using computerized data to identify males at high risk for fracture. Osteoporos Int, 23(3), 1017-27. (Read full article)
- LaFleur J, Nelson RE, Sauer BC, Nebeker JR (2011). Overestimation of the effects of adherence on outcomes: a case study in healthy user bias and hypertension. Heart, 97(22), 1862-9. (Read full article)
- Nelson RE, McAdam-Marx C, Evans ML, Ward R, Campbell B, Brixner D, Lafleur J (2011). Patent Extension Policy for Paediatric Indications: An Evaluation of the Impact within Three Drug Classes in a State Medicaid Programme. Appl Health Econ Health Policy, 9(3), 171-81. (Read full article)
- LaFleur J, McAdam-Marx C, Alder SS, Sheng X, Asche CV, Nebeker J, Brixner DI, Silverman SL (2011). Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. J Bone Miner Metab, 29(2), 193-200. (Read full article)
Abstract
- LaFleur J, Nelson RE, Hoop R, Morgan T, Pandya P, Nelson SD, Hamzeh F (2011). Many United States veterans with chronic hepatitis-C discontinue pegylated interferon therapy for reasons other than non-response. [Abstract]. Hepatology, 54(4), 799a.
- LaFleur J, Ghate SR, Sauer B (2008). Updating the RxRisk-V: Creating a crosswalk between VA and FirstDataBank therapeutic categories. (Poster session presented at International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting. Toronto, Ontario, Canada. May 2008) [Abstract]. Value In Health, 11(3), A191.
- Ghate SR, LaFleur J, Sauer B, Charland S (2008). A modified RxRisk-V comorbidity index predicts adherence with lipid lowering therapy. (Poster session presented at International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting. Toronto, Ontario, Canada. May 2008) [Abstract]. Value In Health, 11(3), A185.